Papaverine, 20 mg/ml 2 ml 10 pcs

Pharmacotherapeutic group:

Spasmodic agent (A03AD01).

Pharmacological group:

Papaverine reduces smooth muscle tone and has a vasodilator and antispasmodic effect in this regard.

It is an inhibitor of phosphodiesterase enzyme and causes intracellular accumulation of cyclic 3,5-adenosine monophosphate, which leads to disruption of smooth muscle contractility and their relaxation in spastic conditions.

The action of papaverine on the CNS is weak, only in high doses it has some sedative effect.

In large doses it reduces excitability of the heart muscle and slows intracardiac conduction.

Indications

Spasms of smooth muscles of the abdominal organs, peripheral and cerebral vessels, urinary tract, renal colic. Used as an adjuvant for premedication.

Pharmacological effect

Pharmacotherapeutic group:

antispasmodic (A03AD01).

Pharmacological group:

Papaverine reduces smooth muscle tone and therefore has a vasodilator and antispasmodic effect.

It is an inhibitor of the phosphodiesterase enzyme and causes intracellular accumulation of cyclic 3,5-adenosine monophosphate, which leads to impaired contractility of smooth muscles and their relaxation during spastic conditions.

The effect of papaverine on the central nervous system is weak; only in large doses does it have some sedative effect.

In large doses, it reduces the excitability of the heart muscle and slows down intracardiac conduction.

Special instructions

The drug should be prescribed with caution and in small doses to elderly and debilitated patients, as well as patients with traumatic brain injury, impaired liver and kidney function, hypothyroidism, adrenal insufficiency, prostatic hypertrophy, as well as patients with supraventricular tachycardia and those in a state of shock.

The drug should be administered intravenously slowly and under the supervision of a physician. During the treatment period, alcohol intake should be avoided. During pregnancy and lactation, the safety of the drug has not been established.

Active ingredient

Papaverine

Composition

1 ml of solution contains 0.02 g of papaverine hydrochloride.

Excipients:

disodium salt of ethylenediaminetetraacetic acid (trilon B),

methionine,

water for injections.

Contraindications

Coma; respiratory depression; disturbance of atrioventricular conduction; age up to 1 year; hypersensitivity to the drug.

Side Effects

Possible drowsiness, headache, nausea, constipation, increased sweating.

With rapid intravenous administration, as well as with the use of high doses, the development of atrioventricular block and heart rhythm disturbances are possible.

Interaction

Papaverine reduces the antiparkinsonian effect of levodopa.

In combination with barbiturates, the antispasmodic effect of papaverine hydrochloride is enhanced.

When used together with tricyclic antidepressants, povocaipamide, reserpine, quinidine sulfate, the hypotensive effect may be enhanced.

Manufacturer

Biokhimik JSC, Russia